Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

ACI’s 7th Annual Advanced Forum on ITC Litigation & Enforcement

Summary

Speakers

Mark J. Abate

Related Content

USPTO’s New Guidance on AI-Assisted Inventions: The Impact on the Use of AI in the Life Sciences

USPTO Issues New Guidance on Patenting AI-Assisted Inventions

What’s Next for AI? Six Areas to Watch in 2024

How To Reduce the Risk of Copyright Infringement When Using Generative AI To Write Code

Coding with AI in an Open-Source World

In re Cellect: Federal Circuit Opens New Path for Double Patenting Challenges

Biden Executive Order Puts Focus on Domestic Manufacturing of Inventions Created Using Federal Funding

Sens. Tillis and Coons Propose New Legislation Regarding Patentability Under § 101

PLI's Patent Law Institute 2024: Critical Issues & Best Practices San Francisco

Dispute Resolution in the Life Sciences Industry

IP Leadership Executive North America 2024

Fox Robotics Enters Multi-Year Agreement with Walmart

Goodwin Advises Exclusive Placement Agent in Acrivon Therapeutics’ $130 Million Private Placement

Auradine Raises $80 Million in Series B Financing and Achieves $80 Million in Bookings

Terragia Biofuel Completes $6 Million Seed Round

The Fate of the Therapeutic Dosing Regimen: Trends and Considerations in Validity Challenges to Dosing Patent Claims

Intellectual Property